Gross Profit Margin (Quarterly) Chart

Historical Gross Profit Margin (Quarterly) Data

View and export this data back to 1997. Start Trial.
Date Value
June 30, 2026 46.46%
March 31, 2026 45.69%
December 31, 2025 45.91%
September 30, 2025 47.50%
June 30, 2025 47.29%
March 31, 2025 41.54%
December 31, 2024 43.25%
September 30, 2024 46.26%
June 30, 2024 46.23%
March 31, 2024 45.67%
December 31, 2023 43.07%
September 30, 2023 33.44%
June 30, 2023 43.05%
March 31, 2023 46.36%
December 31, 2022 46.51%
September 30, 2022 43.60%
June 30, 2022 44.54%
March 31, 2022 44.48%
December 31, 2021 47.05%
September 30, 2021 43.04%
June 30, 2021 42.50%
March 31, 2021 45.77%
December 31, 2020 52.04%
September 30, 2020 46.11%
June 30, 2020 43.06%
Date Value
March 31, 2020 40.75%
December 31, 2019 46.82%
September 30, 2019 49.43%
June 30, 2019 47.68%
March 31, 2019 47.06%
December 31, 2018 47.43%
September 30, 2018 47.55%
June 30, 2018 47.12%
March 31, 2018 38.04%
December 31, 2017 50.32%
September 30, 2017 49.08%
June 30, 2017 49.52%
March 31, 2017 48.23%
December 31, 2016 49.69%
September 30, 2016 48.03%
June 30, 2016 48.37%
March 31, 2016 48.35%
December 31, 2015 47.15%
September 30, 2015 46.71%
June 30, 2015 38.08%
March 31, 2015 51.00%
December 31, 2014 50.95%
September 30, 2014 50.09%
June 30, 2014 51.51%
March 31, 2014 50.82%

Gross Profit Margin Definition

Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.

Read full definition.

Gross Profit Margin (Quarterly) Range, Past 5 Years

View Gross Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Gross Profit Margin (Quarterly) Benchmarks

View Gross Profit Margin (Quarterly) Benchmarks
Start Trial
Abbott Laboratories 52.64%
Boston Scientific Corp. 66.50%
Stryker Corp. 66.14%
Baxter International, Inc. 33.55%
DexCom, Inc. 63.44%